Date:	9/27/2022	
Your Name:	Ira Driscoll	
Manuscript Title:	AD-associated CSF biomolecular changes are attenuated in KL-VS heterozygotes	
Manuscript Number (if known):	DADM-D-21-00193R2	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		e all entities with whom you have this ionship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	None	Click the tab key to add additional rows.
		Time frame: past 36 month	IS
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
3	Royalties or licenses	☑         None	
4	Consulting fees	☑         None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	⊠ None	
7	Support for attending meetings and/or travel	⊠ None	
8	Patents planned, issued or pending	⊠ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	⊠ None	
10	Leadership or fiduciary role in other board,	⊠ None	

		Name all entities with whom you have this elationship or indicate none (add rows as needed) Specifications/Comments (e.g., if payments were made to you or to your institution)	
	society, committee or advocacy group, paid or unpaid		1
11	Stock or stock options	☑       None         □       □         □       □         □       □         □       □	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	☑       None         □       □         □       □         □       □	
13	Other financial or non-financial interests	None	
Please place an "X" next to the following statement to indicate your agreement:			

Date:	9/27/2022	
Your Name:	Yue Ma	
Manuscript Title:	AD-associated CSF biomolecular changes are attenuated in KL-VS heterozygotes	
Manuscript Number (if known):	DADM-D-21-00193R2	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

.g., if payments were
tution)
WS.
WS.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
3	Royalties or licenses	☑         None	
4	Consulting fees	☑         None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	⊠ None	
7	Support for attending meetings and/or travel	⊠ None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	⊠ None	
10	Leadership or fiduciary role in other board,	□ None	

		Name all entities with whom you have thisSpecifications/Comments (e.g., if payments wererelationship or indicate none (add rows as needed)made to you or to your institution)	
	society, committee or advocacy group, paid or unpaid	Member of the Alzheimer's Association International Society to Advance Alzheimer's Research and Treatment (ISTAART)	
11	Stock or stock options	☑       None         ☑       ☑         ☑       ☑         ☑       ☑	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non-financial interests	None	
Please place an "X" next to the following statement to indicate your agreement:			

Date:	9/27/2022	
Your Name:	Sarah Lose	
Manuscript Title:	AD-associated CSF biomolecular changes are attenuated in KL-VS heterozygotes	
Manuscript Number (if known):	DADM-D-21-00193R2	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		e all entities with whom you have this ionship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	None	Click the tab key to add additional rows.
		Time frame: past 36 month	IS
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
3	Royalties or licenses	☑         None	
4	Consulting fees	☑         None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	⊠ None	
7	Support for attending meetings and/or travel	⊠ None	
8	Patents planned, issued or pending	⊠ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	⊠ None	
10	Leadership or fiduciary role in other board,	⊠ None	

		Name all entities with whom you have this elationship or indicate none (add rows as needed) Specifications/Comments (e.g., if payments were made to you or to your institution)	
	society, committee or advocacy group, paid or unpaid		1
11	Stock or stock options	☑       None         □       □         □       □         □       □         □       □	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	☑       None         □       □         □       □         □       □	
13	Other financial or non-financial interests	None	
Please place an "X" next to the following statement to indicate your agreement:			

Date:	9/19/2022
Your Name:	Catherine Gallagher
Manuscript Title:	AD-associated CSF biomolecular changes are attenuated in KL-VS heterozygotes
Manuscript Number (if known):	Article ID: DAD212330Article DOI: 10.1002/dad2.12330Internal Article ID: 17410729

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		e all entities with whom you have this ionship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	Click the tab key to add additional rows.
		Time frame: past 36 month	s
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
3	Royalties or licenses	☑         None	
4	Consulting fees	☑         None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	⊠ None	
7	Support for attending meetings and/or travel	⊠ None	
8	Patents planned, issued or pending	⊠ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	⊠ None	
10	Leadership or fiduciary role in other board,	⊠ None	

		Iame all entities with whom you have thisSpecifications/Comments (e.g., if payments wereelationship or indicate none (add rows as needed)made to you or to your institution)	
	society, committee or advocacy group, paid or unpaid		
11	Stock or stock options	☑       None         ☑       □         ☑       □         ☑       □         ☑       □	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	☑       None         □       □         □       □         □       □	
13	Other financial or non-financial interests	None	
Plea	Please place an "X" next to the following statement to indicate your agreement:		

Date:	9/28/2022	
Your Name:	Sterling Johnson	
Manuscript Title:	AD-associated CSF biomolecular changes are attenuated in KL-VS heterozygotes	
Manuscript Number (if known):	DADM-D-21-00193R2	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present	□ None	
	manuscript (e.g.,	NIH R01AGO27161, NIH R01AG021155	Grant to Institution
	funding, provision	Cerveau Technologies	Grant to Institution
	of study materials,		Click the tab key to add additional rows.
	medical writing,		
	article processing		
	charges, etc.)		
	No time limit for		
	this item.		
		Time frame: past 36 month	s
2	Grants or contracts from	⊠ None	
	any entity (if not		
	indicated in item		
	#1 above).		

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
3	Royalties or licenses	☑     None	
4	Consulting fees	None     Roche Diagnostics     Eisai	Payment to Individual Payment to Individual
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	⊠ None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	⊠ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board,	□ None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	society, committee or advocacy group, paid or unpaid	Past Chair of the national ADRC Imaging Core Steering committee	
11	Stock or stock options	⊠ None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None     Equipment Grant from Roche Diagnostics	To Institution
13	Other financial or non-financial interests	⊠ None	
Plea ×	Please place an "X" next to the following statement to indicate your agreement:		

Date:	10/14/2022	
Your Name:	Sanjay Asthana	
Manuscript Title:	AD-associated CSF biomolecular changes are attenuated in KL-VS heterozygotes	
Manuscript Number (if known):	DADM-D-21-00193R2	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		e all entities with whom you have this ionship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	None	Click the tab key to add additional rows.
		Time frame: past 36 month	IS
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
3	Royalties or licenses	☑         None	
4	Consulting fees	☑         None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	⊠ None	
7	Support for attending meetings and/or travel	⊠ None	
8	Patents planned, issued or pending	⊠ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	⊠ None	
10	Leadership or fiduciary role in other board,	⊠ None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	society, committee or advocacy group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	☑ None	
13	Other financial or non-financial interests	None       Genentech       Merck       Lundbeck	Grant to serve as a site PI for a clinical trial; grant awarded to the University Grant to serve as a site PI for a clinical trial; grant awarded to the University Grant to serve as a site PI for a clinical trial; grant awarded to the University
Plea ×		t to the following statement to indicate your agreeme answered every question and have not altered the wo	

Date:	9/26/2022
Your Name:	Bruce Hermann
Manuscript Title:	Click or tap here to enter text.
Manuscript Number (if known):	Click or tap here to enter text.

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

			e all entities with whom y ionship or indicate none (		Specifications/Comments (e. made to you or to your instit	
			Time frame: Sir	ce the initial planning	of the work	
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>		None	Click the tab key to add a	dditional rows.	
			Time	frame: past 36 month	S	
2	Grants or contracts from any entity (if not indicated in item #1 above).	NII NII NII	None H R01 NS120976 H R01 NS111022 H R01 NS117568 H R01 AG027161			

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
3	Royalties or licenses	None	
4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	☑ None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	⊠ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None     Medtronics	Epilepsy surgery investigation
10	Leadership or fiduciary role in other board,	⊠ None	

		Name all entities with whom you have thisSpecifications/Comments (e.g., if payments were relationship or indicate none (add rows as needed)made to you or to your institution)	e	
	society, committee or advocacy group, paid or unpaid			
11	Stock or stock options	None		
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	☑         None		
13	Other financial or non-financial interests	None	-	
Please place an "X" next to the following statement to indicate your agreement:				

Date:	9/27/2022
Your Name:	Mark A Sager
Manuscript Title:	AD-associated CSF biomolecular changes are attenuated in KL-VS heterozygotes
Manuscript Number (if known):	DADM-D-21-00193R2

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		e all entities with whom you have this ionship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	None	Click the tab key to add additional rows.
		Time frame: past 36 month	IS
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
3	Royalties or licenses	☑         None	
4	Consulting fees	☑         None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	⊠ None	
7	Support for attending meetings and/or travel	⊠ None	
8	Patents planned, issued or pending	⊠ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	⊠ None	
10	Leadership or fiduciary role in other board,	⊠ None	

		Name all entities with whom you have this elationship or indicate none (add rows as needed) Specifications/Comments (e.g., if payments were made to you or to your institution)		
	society, committee or advocacy group, paid or unpaid		1	
11	Stock or stock options	☑       None         □       □         □       □         □       □         □       □		
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	☑       None         □       □         □       □         □       □		
13	Other financial or non-financial interests	None		
Please place an "X" next to the following statement to indicate your agreement:				

Date:	9/27/2022
Your Name:	Kaj Blennow
Manuscript Title:	AD-associated CSF biomolecular changes are attenuated in KL-VS heterozygotes
Manuscript Number (if known):	DADM-D-21-00193R2

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

			es with whom you have this indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
			Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g.,	None		
	funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.			Click the tab key to add additional rows.
			Time frame: past 36 mont	ns
2	Grants or contracts from any entity (if not indicated in item #1 above).	None		

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
3	Royalties or licenses	☑ None	
4	Consulting fees	None Abcam, Axon, Biogen, JOMDD/Shimadzu, Julius Clinical, Lilly, MagQu, Novartis, Prothena, Roche Diagnostics, and Siemens Healthineers	Payments made to KB.
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	⊠ None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	⊠ None	
8	Patents planned, issued or pending	⊠ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None Abcam, Axon, Biogen, JOMDD/Shimadzu, Julius Clinical, Lilly, MagQu, Novartis, Prothena, Roche Diagnostics, and Siemens Healthineers.	Payments made to KB.

		Name all entities with whom you have this elationship or indicate none (add rows as needed) Specifications/Comments (e.g., if payments were made to you or to your institution)	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None         Co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work).       Payments made to KB.         Image: Comparison of the GU Work of the GU       Payments made to KB.	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	☑       None         ☑       □         ☑       □         ☑       □	
13	Other financial or non-financial interests	None	
Plea 🖂	Please place an "X" next to the following statement to indicate your agreement:		

Date:\_\_\_\_\_2022-09-23\_\_\_

Your Name: \_Henrik Zetterberg\_

Manuscript Title: AD-associated CSF biomolecular changes are attenuated in KL-VS heterozygotes Manuscript number (if known): DADM-D-21-00193R2

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	(e.g., if	cations/Comments payments were made or to your institution)
		Time frame: Since the initial plan	ning of tl	ne work
1	All support for the present	HZ is a Wallenberg Scholar supported by	grants	Payments made to Institution.
	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	from the Swedish Research Council (#201 02532), the European Union's Horizon Eu research and innovation programme under agreement No 101053962, Swedish State for Clinical Research (#ALFGBG-71320), th Alzheimer Drug Discovery Foundation (AE USA (#201809-2016862), the AD Strategic and the Alzheimer's Association (#ADSF-2 831376-C, #ADSF-21-831381-C, and #ADS 831377-C), the Bluefield Project, the Olav Foundation, the Erling-Persson Family Foundation, Stiftelsen för Gamla Tjänarin Hjärnfonden, Sweden (#FO2022-0270), th European Union's Horizon 2020 research innovation programme under the Marie	8- rope er grant Support ne DDF), : Fund 1- F-21- Thon nor, ne	

	Name all entities with whom you have this relationship or indicate none (add rows as needed)	(e.g., if	cations/Comments payments were made or to your institution)	
No time limit for this item.	Skłodowska-Curie grant agreement No 86 (MIRIADE), the European Union Joint Prog – Neurodegenerative Disease Research (JPND2021-00694), and the UK Dementia Research Institute at UCL (UKDRI-1003).	gramme		
			Click the tab key to add additional rows	
	Time frame: past 36 mo	onths		
2 Grants or contracts from any entity (if not indicated in item #1 above).	□ None HZ is a Wallenberg Scholar support by grants from the Swedish Reset Council (#2018-02532), the Europort Union's Horizon Europe research innovation programme under gra- agreement No 101053962, Swed State Support for Clinical Researce (#ALFGBG-71320), the Alzheime Discovery Foundation (ADDF), US (#201809-2016862), the AD Strater Fund and the Alzheimer's Associa (#ADSF-21-831376-C, #ADSF-21 831381-C, and #ADSF-21-831377 the Bluefield Project, the Olav Th Foundation, the Erling-Persson F Foundation, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweder (#FO2022-0270), the European U Horizon 2020 research and innov programme under the Marie Skłodowska-Curie grant agreemer 860197 (MIRIADE), the European Union Joint Programme – Neurodegenerative Disease Rese (JPND2021-00694), and the UK Dementia Research Institute at U (UKDRI-1003).	arch opean and ant ish ch r Drug SA ategic ation - 7-C), on amily en Jnion's vation ent No n arch	Payments made to Institu	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	(e.g., if	cations/Comments payments were made or to your institution)
3	Royalties or licenses	☑ None		
4	Consulting fees	NoneHZ has served at scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, ALZPath, Annexon, Apellis, Artery Therapeutics, AZTherapies, CogRx, Denali, Eisai, Nervgen, Novo Nordisk, Passage Bio, Pinteon Therapeutics, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave.Payments made to HZ.		
5	Payment or honoraria for lectures, presentati ons, speakers bureaus, manuscrip t writing or education al events	<ul> <li>□ None</li> <li>HZ has given lectures in symposis sponsored by Fujirebio, Alzecure Cellectricon, Biogen, and Roche.</li> </ul>		Payments made to HZ.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	(e.g., if )	cations/Comments payments were made or to your institution)
6	Payment for expert testimony	⊠ None		
7	Support for attending meetings and/or travel	⊠ None		
8	Patents planned, issued or pending	⊠ None		
9	Participati on on a Data Safety Monitorin g Board or Advisory Board	□ None HZ has served at scientific advise boards and/or as a consultant fo Abbvie, Acumen, Alector, ALZPat Annexon, Apellis, Artery Therape AZTherapies, CogRx, Denali, Eisa Nervgen, Novo Nordisk, Passage Pinteon Therapeutics, Red Abbey reMYND, Roche, Samumed, Siem Healthineers, Triplet Therapeuti Wave.	r ch, eutics, i, Bio, y Labs, ens	Payments made to HZ.
1 0	Leadership or fiduciary role in other board, society,	<ul> <li>□ None</li> <li>HZ is chair of the Alzheimer's Association Global Biomarker Standardization Consortium.</li> </ul>		No payments made.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	(e.g., if	cations/Comments payments were made or to your institution)
	committee or advocacy group, paid or unpaid			
1	Stock or stock options	□ None HZ is a co-founder of Brain Bioma Solutions in Gothenburg AB (BBS which is a part of the GU Ventures Incubator Program.	),	Payments made to HZ.
1 2	Receipt of equipment , materials, drugs, medical writing, gifts or other services	⊠ None		
13	Other financial or non- financial interests	⊠ None		

# Please place an "X" next to the following statement to indicate your agreement:

I certify that I have answered every question and have not altered the wording  $\boxtimes$  of any of the questions on this form.

Date:	10/18/2022			
Your Name:	Cynthia M. Carlsson			
Manuscript Title:	AD-associated CSF biomolecular changes are attenuated in KL-VS heterozygotes			
Manuscript Number (if known):	DADM-D-21-00193R2			

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning o	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	⊠ None	Click the tab key to add additional rows.
		Time frame: past 36 months	3
2	Grants or contracts from any entity (if not indicated in item #1 above).	None         VA Merit grant (to institution), Amarin Corp (study drugs for VA Merit study),         NIH/Lilly A4 study (funding to institution, site PI), NIH/Eisai for AHEAD study (funding to institution, site PI), NIH ARMADA Study (funding to institution, site PI), NIH ACTC TRC-PAD study (funding to institution, site PI)	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
3	Royalties or licenses	None	
4	Consulting fees	⊠ None	
5	Payment or	⊠ None	
5	honoraria for		
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for	⊠ None	
	expert testimony		
7	7     Support for attending     None		
	meetings and/or travel	HHS travel support to attend Advisory Council meet	ing (NAPA)
8	Patents planned,	⊠ None	
	issued or pending		
	pending		
9	Participation on a Data Safety	□ None	
	Monitoring	TDAD study DSMB (NIH funded)	No payment
	Board or Advisory Board	US POINTER DSMB (Alz Assoc Funded) D-CARE study DSMB (NIH funded)	No payment Honorarium to me
10	Leadership or fiduciary role in other board,	□ None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)				
	society, committee or	Chair, US HHS Advisory Council on Alzheimer's Research, Care and Services	Travel costs covered				
	advocacy group, paid or unpaid	Co-Chair, NIA ADRC Program Clinical Task Force Clinical Measures Subcommittee	One time honorarium				
11	Stock or stock options	⊠ None					
12	Receipt of equipment,	□ None					
	materials, drugs, medical writing, gifts or other services	Amarin Corp	Study drugs for VA-funded clinical trial				
13	Other financial or non-financial	⊠ None					
	interests						
Plea	Please place an "X" next to the following statement to indicate your agreement:						
$\boxtimes$	I certify that I have answered every question and have not altered the wording of any of the questions on this form.						

Date:	10/16/2022			
Your Name:	Corinne Engelman			
Manuscript Title:	AD-associated CSF biomolecular changes are attenuated in KL-VS heterozygotes			
Manuscript Number (if known):	DADM-D-21-00193R2			

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		e all entities with whom you have this ionship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	None	Click the tab key to add additional rows.
		Time frame: past 36 month	IS
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
3	Royalties or licenses	☑         None	
4	Consulting fees	☑         None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	⊠ None	
7	Support for attending meetings and/or travel	⊠ None	
8	Patents planned, issued or pending	⊠ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	⊠ None	
10	Leadership or fiduciary role in other board,	⊠ None	

		Name all entities with whom you have this elationship or indicate none (add rows as needed) Specifications/Comments (e.g., if payments were made to you or to your institution)	
	society, committee or advocacy group, paid or unpaid		
11	Stock or stock options	☑       None         ☑       ☑         ☑       ☑         ☑       ☑	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	☑         None	
13	Other financial or non-financial interests	None	
Plea	Please place an "X" next to the following statement to indicate your agreement:		

Date:	10/14/2022
Your Name:	Dena Dubal
Manuscript Title:	AD-associated CSF biomolecular changes are attenuated in KL-VS heterozygotes
	Ineterozygotes
Manuscript Number (if known):	DADM-D-21-00193R2

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

				vhom you have this none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
			Time fra	me: Since the initial planning	of the work
1	All support for the present		None		
	manuscript (e.g.,	NIF	I R01NS092918		
	funding, provision				
	of study materials,				Click the tab key to add additional rows.
	medical writing,				
	article processing				
	charges, etc.) <b>No time limit for</b>				
	this item.				
				Time frame: past 36 months	S
2	Grants or		None		
	contracts from				
	any entity (if not	Rec	eived funding from	the Simons Foundation.	
	indicated in item		<u> </u>		
	#1 above).				

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
3	Royalties or licenses	☑         None	
4	Consulting fees	None     Received consulting fees from SV Health Investors	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None           Received honoraria for giving lectures at           Universities.	
6	Payment for expert testimony	⊠ None	
7	Support for attending meetings and/or travel	None     Received travel support from the Simons     Foundation.	
8	Patents planned, issued or pending	None The University of California San Francisco holds pending and granted patents regarding klotho and methods of improving cognition.	
9	Participation on a Data Safety Monitoring Board or Advisory Board	☑         None	
10	Leadership or fiduciary role in	□ None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	other board, society, committee or advocacy group, paid or unpaid	Board member of ANA and Scientific Advisor Board Member of Glenn Foundation.	
11	Stock or stock options	None Hold stock options in Unity Biotechnology.	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	⊠ None	
13	Other financial or non-financial interests	None	
Plea	Please place an "X" next to the following statement to indicate your agreement:		

Date:	9/30/2022
Your Name:	Ozioma Okonkwo
Manuscript Title:	AD-associated CSF biomolecular changes are attenuated in KL-VS heterozygotes
Manuscript Number (if known):	DADM-D-21-00193R2

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

			e all entities with whom you have this ionship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
			Time frame: Since the initial planning	of the work
1	All support for the present		None	
	manuscript (e.g.,	NIH		
	funding, provision			
	of study materials,			Click the tab key to add additional rows.
	medical writing,			
	article processing			
	charges, etc.)			
	No time limit for			
	this item.			
			Time frame: past 36 month	S
2	Grants or	$\boxtimes$	None	
	contracts from			
	any entity (if not			
	indicated in item			
	#1 above).			
	- , .			

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
3	Royalties or licenses	☑     None	
4	Consulting fees	None     Rebalanced-Life Wellness Association	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None Honoraria for presentation	
6	Payment for expert testimony	⊠ None	
7	Support for attending meetings and/or travel	☑     None	
8	Patents planned, issued or pending	☑         None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	⊠         None	
10	Leadership or fiduciary role in other board,	None     International Neuropsychological Society	

		ame all entities with whom you have thisSpecifications/Comments (e.g., if payments wereelationship or indicate none (add rows as needed)made to you or to your institution)	
	society, committee or advocacy group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non-financial interests	None	
Plea	Please place an "X" next to the following statement to indicate your agreement:		